HRMY

HARMONY BIOSCIENCES HOLDINGS INC

Healthcare | Mid Cap

$1.09

EPS Forecast

$274

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Harmony Biosciences’ Q2 Wake-Up Call: WAKIX Powering Growth as BP-205 Pushes Toward Phase 2

HRMY, EPS, EPS consensus, earnings surprise, revenue forecast — a look at how Harmony’s second quarter shapes the year and what it could mean for peers in the wakeful CNS arena.

Q2 Highlights: Steady Demand and reaffirmed revenue forecast

Harmony Biosciences reported Q2 2026 net revenue of $261.3 million, up 30% year over year, underscoring durable demand for its flagship WAKIX (pitolisant) franchise. The company also noted that average patients for the quarter rose to about 8,950, a gain of roughly 450 patients versus the prior period.

Management reaffirmed its revenue forecast for the full year, guiding net revenue of $1.0 billion to $1.04 billion for 2026. In other words, strength is carrying into the back half, and the math suggests a growth story that looks less like luck and more like territory control in a competitive wakefulness space.

The press release did not publish an EPS figure or an explicit earnings surprise relative to an EPS consensus from street estimates. In typical corporate cadence, investors will soon reconcile the top-line beat with per-share implications as analysts model margins, operating leverage, and any one-time items—if/when those surface—against the revenue narrative.

Pipeline momentum: BP-205 and the orexin strategy

Beyond WAKIX, Harmony highlighted encouraging single ascending dose data from its Phase 1 program for BP-205, an orexin-2 receptor (OX2R) agonist. The company described the PK and safety/tolerability data as favorable, reinforcing its conviction that BP-205 could become a best-in-class orexin-2 agonist in the CNS space. The data support Harmony’s plan to initiate Phase 2 trials in mid-2027 to evaluate multiple CNS indications.

In parallel, the Phase 1 program for BP-205 includes a MAD dataset expected in Q4 2026, and the company signaled continued progress on regulatory pathways, including an open IND in the US and the pursuit of additional Phase 1b studies in sleep-deprived healthy volunteers in Q3, with early data anticipated in 2027.

Regulatory runway for pitolisant and potential milestones

Harmony noted that Pitolisant NDA (GR) was accepted in July with a target PDUFA date set for April 1, 2027, indicating near-term catalyst exposure for the WAKIX franchise from a regulatory perspective.

A separate pathway for Pitolisant in a different indication (HD) is described as on track for Phase 3 topline data in 2027 and a PDUFA date in 2028, suggesting multiple regulatory milestones that could support a longer-term growth narrative if the data hold up.

What this could mean for the stock and the sector

The combination of continued revenue strength and a robust pipeline could reinforce HRMY’s positioning as a revenue-generating wakefulness specialist with a meaningful near-term revenue floor and a longer-term pipeline optionality. For revenue forecast players and investors focusing on durable franchises, the Q2 numbers reinforce a thesis that growth is not solely a function of price moves or one-off events, but of sustained demand and portfolio breadth.

From a competitive vantage point, the BP-205 advancement underscores a broader trend in CNS development: companies are betting on targeted receptor biology to unlock new indications and potentially better safety/tolerability profiles. If BP-205 demonstrates compelling PK/PD and tolerability in early-stage data, the sector could see heightened activity around orexin-2 strategies and related wake-promoting therapies.

What to watch next

Key items for investors and observers include: the ongoing execution of BP-205’s Phase 1b/Phase 2 roadmap, the timing and clarity of MAD data in Q4 2026, the PDUFA dates for Pitolisant across its indications, and any updates to the 2026 revenue trajectory as the year progresses.

In the near term, analysts will likely translate Harmony’s top-line strength into per-share expectations, weighing the absence or presence of explicit EPS data against the revenue narrative. Even without a reported EPS consensus in the release, the equity story could hinge on how well the company converts revenue into margin and how effectively BP-205—and any additional assets—translate into a materials-based uplift for earnings in future periods.

Closing thought: a wakeful, profitable horizon

Harmony’s Q2 results read like a business that has found a cadence—strong demand for a core product, a growing patient base, and a pipeline that promises optionality beyond the obvious. If BP-205 can deliver in early-stage reads and the regulatory clock keeps ticking toward the 2027–2028 milestones, HRMY could cement a multi-year investment narrative in a space that rewards both steady execution and strategic bets on novel mechanisms.

Disclaimer: This article synthesizes information from Harmony Biosciences’ Q2 2026 disclosures. Figures reflect company-reported numbers and guidance as of August 4, 2026. Investors should consider EPS, earnings surprise, EPS consensus, and revenue forecast details in diligence as more data become available.